New Celselect slides™ design increases efficiency of circulating tumor cell capture from liquid biopsy samples for enumeration and downstream applications.

AMP published a set of evidence-based recommendations for the analytical validation and reporting of tumor mutational burden (TMB) testing as a potential predictive biomarker for immune checkpoint inhibitor (ICI) therapies.

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy (CAR-T cell therapy) for patients in Estonia.

Plasma-based proteomic platform predicts clinical benefit from immune-checkpoint inhibitors in NSCLC, melanoma, and HPV-related cancers.

Optimer binders will be developed for use in a cervical cancer blood test. Agreement for up to £465,000 signed for Optimer development.

On April 29th, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.